N- (4-hydroxy-4-methyl-cyclohexyl) -4-phenyl-benzenesulfonamide compound and N- (4-hydroxy-4-methyl-cyclohexyl) -4- (2-pyridyl)- Benzenesulfonamide compounds and their therapeutic use
The present invention relates generally to the field of therapeutic compounds. More specifically, the invention relates to disorders mediated by, for example, inflammation and / or joint destruction and / or bone loss, excessive and / or inappropriate and / or long-term activation of the immune system, Inflammatory and autoimmune disorders such as rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), asthma, atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, multiple sclerosis, systemic Disorders associated with bone loss such as systemic lupus erythematosus, Sjogren's syndrome, bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-related bone disease, or Paget's disease, multiple myeloma, leukemia, Or hematological malignancies such as lymphoma, or bladder cancer, breast cancer (female and / or male), colon cancer, renal cell cancer, renal cancer, lung cancer, pancreatic cancer, gastric cancer, prostate cancer, brain cancer, skin Cancers such as cancer, thyroid cancer, basal cell enamel epithelioma, or solid tumor cancers such as melanoma, disorders related to fibrosis such as systemic scleroderma or scleroderma, or Behcet's disease Certain substituted N- (4-hydroxy-4-methyl-cyclohexyl) -4-phenyl-benzenesulfonamide compounds that are useful in the treatment of disorders (eg, diseases), including rare rare vasculitis And N- (4-hydroxy-4-methyl-cyclohexyl) -4- (2-pyridyl) benzenesulfonamide compounds (collectively referred to herein as HMC compounds). The invention also relates to pharmaceutical compositions comprising such compounds and the use of such compounds and compositions, for example in therapy. [Selection figure] None本発明は概して、治療用化合物の分野に関する。より具体的には、本発明は、例えば、炎症及び／または関節破壊及び／または骨量減少、免疫系の過剰な及び／または不適切な及び／または長期間の活性化によって仲介される障害、炎症性障害及び自己免疫障害、例えば、関節リウマチ、乾癬、乾癬性関節炎、慢性閉塞性肺疾患（ＣＯＰＤ）、喘息、粥状硬化、炎症性腸疾患、強直性脊椎炎、多発性硬化症、全身性エリテマトーデス、シェーグレン症候群、関節リウマチにおける過剰な破骨細胞活性と関係する骨量減少
